Effect of deubiquitinases in head and neck squamous cell carcinoma (Review)
- Authors:
- Jiahui Wang
- Liangpei Wu
- Zhifeng Tian
- Jun Chen
-
Affiliations: Department of Chemoradiotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang 315040, P.R. China, Cancer Center, Lishui Municipal Central Hospital, Lishui, Zhejiang 323000, P.R. China - Published online on: April 23, 2025 https://doi.org/10.3892/ol.2025.15053
- Article Number: 307
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
|
Parmar K, Mohamed A, Vaish E, Thawani R, Cetnar J and Thein KZ: Immunotherapy in head and neck squamous cell carcinoma: An updated review. Cancer Treat Res Commun. 33:1006492022. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE and Grandis JR: Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 6:922020. View Article : Google Scholar : PubMed/NCBI | |
|
McDermott JD and Bowles DW: Epidemiology of head and neck squamous cell carcinomas: Impact on staging and prevention strategies. Curr Treat Options Oncol. 20:432019. View Article : Google Scholar : PubMed/NCBI | |
|
Bhatia A and Burtness B: Treating head and neck cancer in the age of immunotherapy: A 2023 update. Drugs. 83:217–248. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Daste A, Larroquette M, Gibson N, Lasserre M and Domblides C: Immunotherapy for head and neck squamous cell carcinoma: Current status and perspectives. Immunotherapy. 16:187–197. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YJ, Lee Y, Shin H, Hwang S, Park J and Song EJ: Ubiquitin-proteasome system as a target for anticancer treatment-an update. Arch Pharm Res. 46:573–597. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Xiang Y, Fan M, Fang S and Hua Q: The ubiquitin-proteasome system in tumor metabolism. Cancers (Basel). 15:23852023. View Article : Google Scholar : PubMed/NCBI | |
|
Schulman BA and Harper JW: Ubiquitin-like protein activation by E1 enzymes: The apex for downstream signalling pathways. Nat Rev Mol Cell Biol. 10:319–331. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhai F, Wang J, Yang W, Ye M and Jin X: The E3 ligases in cervical cancer and endometrial cancer. Cancers (Basel). 14:53542022. View Article : Google Scholar : PubMed/NCBI | |
|
Kong L and Jin X: Dysregulation of deubiquitination in breast cancer. Gene. 902:1481752024. View Article : Google Scholar : PubMed/NCBI | |
|
Park J, Cho J and Song EJ: Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 43:1144–1161. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hochstrasser M: Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol. 7:215–223. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Spano D and Catara G: Targeting the ubiquitin-proteasome system and recent advances in cancer therapy. Cells. 13:292023. View Article : Google Scholar : PubMed/NCBI | |
|
Bennett EJ and Harper JW: DNA damage: Ubiquitin marks the spot. Nat Struct Mol Biol. 15:20–22. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Pickart CM and Eddins MJ: Ubiquitin: Structures, functions, mechanisms. Biochim Biophys Acta. 1695:55–72. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Komander D, Clague MJ and Urbé S: Breaking the chains: Structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 10:550–563. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dewson G, Eichhorn PJA and Komander D: Deubiquitinases in cancer. Nat Rev Cancer. 23:842–862. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
D'Arcy P, Wang X and Linder S: Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther. 147:32–54. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Abdul Rehman SA, Kristariyanto YA, Choi SY, Nkosi PJ, Weidlich S, Labib K, Hofmann K and Kulathu Y: MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol Cell. 63:146–155. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jin S, Kudo Y and Horiguchi T: The role of deubiquitinating enzyme in head and neck squamous cell carcinoma. Int J Mol Sci. 24:5522022. View Article : Google Scholar : PubMed/NCBI | |
|
Hu M, Li P, Li M, Li W, Yao T, Wu JW, Gu W, Cohen RE and Shi Y: Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 111:1041–1054. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kuhlbrodt K, Janiesch PC, Kevei É, Segref A, Barikbin R and Hoppe T: The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. Nat Cell Biol. 13:273–281. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nicastro G, Menon RP, Masino L, Knowles PP, McDonald NQ and Pastore A: The solution structure of the Josephin domain of ataxin-3: Structural determinants for molecular recognition. Proc Natl Acad Sci USA. 102:10493–10498. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hurley JH and Stenmark H: Molecular mechanisms of ubiquitin-dependent membrane traffic. Annu Rev Biophys. 40:119–142. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Davies CW, Paul LN, Kim MI and Das C: Structural and thermodynamic comparison of the catalytic domain of AMSH and AMSH-LP: Nearly identical fold but different stability. J Mol Biol. 413:416–429. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liang J, Saad Y, Lei T, Wang J, Qi D, Yang Q, Kolattukudy PE and Fu M: MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling. J Exp Med. 207:2959–2973. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SMY, Krinsky AL, Woolaver RA, Wang X, Chen Z and Wang JH: Tumor immune microenvironment in head and neck cancers. Mol Carcinog. 59:766–774. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gulve N, Su C, Deng Z, Soldan SS, Vladimirova O, Wickramasinghe J, Zheng H, Kossenkov AV and Lieberman PM: DAXX-ATRX regulation of p53 chromatin binding and DNA damage response. Nat Commun. 13:50332022. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Shang L, Zhou F, Wang S, Liu N, Zhou M, Lin Q, Zhang M, Cai Y, Chen G and Yang S: Herba patriniae and its component isovitexin show anti-colorectal cancer effects by inducing apoptosis and cell-cycle arrest via p53 activation. Biomed Pharmacother. 168:1156902023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Guo M, Wei H and Chen Y: Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 8:922023. View Article : Google Scholar : PubMed/NCBI | |
|
Hassin O and Oren M: Drugging p53 in cancer: One protein, many targets. Nat Rev Drug Discov. 22:127–144. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Brummer T and Zeiser R: The role of the MDM2/p53 axis in antitumor immune responses. Blood. 143:2701–2709. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Bradford CR, Zhu S, Poore J, Fisher SG, Beals TF, Thoraval D, Hanash SM, Carey TE and Wolf GT: p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of veterans affairs laryngeal cancer cooperative study group. Arch Otolaryngol Head Neck Surg. 123:605–609. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Nathan CA, Khandelwal AR, Wolf GT, Rodrigo JP, Mäkitie AA, Saba NF, Forastiere AA, Bradford CR and Ferlito A: TP53 mutations in head and neck cancer. Mol Carcinog. 61:385–391. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Koo N, Sharma AK and Narayan S: Therapeutics targeting p53-MDM2 interaction to induce cancer cell death. Int J Mol Sci. 23:50052022. View Article : Google Scholar : PubMed/NCBI | |
|
Kwon SK, Saindane M and Baek KH: p53 stability is regulated by diverse deubiquitinating enzymes. Biochim Biophys Acta Rev Cancer. 1868:404–411. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Saha G, Roy S, Basu M and Ghosh MK: USP7-a crucial regulator of cancer hallmarks. Biochim Biophys Acta Rev Cancer. 1878:1889032023. View Article : Google Scholar : PubMed/NCBI | |
|
Shin SC, Park J, Kim KH, Yoon JM, Cho J, Ha BH, Oh Y, Choo H, Song EJ and Kim EE: Structural and functional characterization of USP47 reveals a hot spot for inhibitor design. Commun Biol. 6:9702023. View Article : Google Scholar : PubMed/NCBI | |
|
Nininahazwe L, Liu B, He C, Zhang H and Chen ZS: The emerging nature of Ubiquitin-specific protease 7 (USP7): A new target in cancer therapy. Drug Discov Today. 26:490–502. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Pozhidaeva A and Bezsonova I: USP7: Structure, substrate specificity, and inhibition. DNA Repair (Amst). 76:30–39. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Brooks CL, Li M, Hu M, Shi Y and Gu W: The p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene. 26:7262–7266. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sacco JJ, Coulson JM, Clague MJ and Urbé S: Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life. 62:140–157. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Niu H, Zhu Y, Wang J, Wang T, Wang X and Yan L: Effects of USP7 on radiation sensitivity through p53 pathway in laryngeal squamous cell carcinoma. Transl Oncol. 22:1014662022. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, Zeng C, Zhou T and Zhang J: NF-κB in biology and targeted therapy: New insights and translational implications. Signal Transduct Target Ther. 9:532024. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Lin L, Zhang Z, Zhang H and Hu H: Targeting NF-κB pathway for the therapy of diseases: Mechanism and clinical study. Signal Transduct Target Ther. 5:2092020. View Article : Google Scholar : PubMed/NCBI | |
|
Tan Y, Sun R, Liu L, Yang D, Xiang Q, Li L, Tang J, Qiu Z, Peng W, Wang Y, et al: Tumor suppressor DRD2 facilitates M1 macrophages and restricts NF-κB signaling to trigger pyroptosis in breast cancer. Theranostics. 11:5214–5231. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Schrank TP, Prince AC, Sathe T, Wang X, Liu X, Alzhanov DT, Burtness B, Baldwin AS, Yarbrough WG and Issaeva N: NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer. Oncotarget. 13:707–722. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lin XL, Darnay BG, Chaturvedi MM and Aggarwal BB: Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene. 26:1385–1397. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Napetschnig J and Wu H: Molecular basis of NF-κB signaling. Annu Rev Biophys. 42:443–468. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Courtois G: Tumor suppressor CYLD: Negative regulation of NF-kappaB signaling and more. Cell Mol Life Sci. 65:1123–1132. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y and Zhou J: CYLD-a deubiquitylase that acts to fine-tune microtubule properties and functions. J Cell Sci. 129:2289–2295. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cui Z, Kang H, Grandis JR and Johnson DE: CYLD alterations in the tumorigenesis and progression of human papillomavirus-associated head and neck cancers. Mol Cancer Res. 19:14–24. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Massoumi R: CYLD: A deubiquitination enzyme with multiple roles in cancer. Future Oncol. 7:285–297. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Verhoeft KR, Ngan HL and Lui VWY: The cylindromatosis (CYLD) gene and head and neck tumorigenesis. Cancers Head Neck. 1:102016. View Article : Google Scholar : PubMed/NCBI | |
|
Deng M, Dai W, Yu VZ, Tao L and Lung ML: Cylindromatosis lysine 63 deubiquitinase (CYLD) regulates NF-kB signaling pathway and modulates fibroblast and endothelial cells recruitment in nasopharyngeal carcinoma. Cancers (Basel). 12:19242020. View Article : Google Scholar : PubMed/NCBI | |
|
Hu B, Zhang D, Zhao K, Wang Y, Pei L, Fu Q and Ma X: Spotlight on USP4: Structure, function, and regulation. Front Cell Dev Biol. 9:5951592021. View Article : Google Scholar : PubMed/NCBI | |
|
Tao Y and You W: The deubiquitinating enzyme USP4 functions as an oncoprotein in gastric cancer and mediates NF-κB signaling by regulating PRL-3 expression. Front Biosci (Landmark Ed). 27:2862022. View Article : Google Scholar : PubMed/NCBI | |
|
Hou X, Wang L, Zhang L, Pan X and Zhao W: Ubiquitin-specific protease 4 promotes TNF-α-induced apoptosis by deubiquitination of RIP1 in head and neck squamous cell carcinoma. FEBS Lett. 587:311–316. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shi A, Liu L, Li S and Qi B: Natural products targeting the MAPK-signaling pathway in cancer: Overview. J Cancer Res Clin Oncol. 150:62024. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y, Chen J, Shi Y, Fang X and Tang Z: MAPK signaling pathway in oral squamous cell carcinoma: Biological function and targeted therapy. Cancers (Basel). 14:46252022. View Article : Google Scholar : PubMed/NCBI | |
|
Roskoski R Jr: ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res. 66:105–143. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ngan HL, Law CH, Choi YCY, Chan JY and Lui VWY: Precision drugging of the MAPK pathway in head and neck cancer. NPJ Genom Med. 7:202022. View Article : Google Scholar : PubMed/NCBI | |
|
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y and Hu LL: ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 19:1997–2007. 2020.PubMed/NCBI | |
|
Wu PK, Becker A and Park JI: Growth inhibitory signaling of the Raf/MEK/ERK pathway. Int J Mol Sci. 21:54362020. View Article : Google Scholar : PubMed/NCBI | |
|
Shen J, Xie M, Xu Y, Qian Q, Qiu T, Shi W, Ren D, Ji J and Huang J: Identification of the deubiquitinase USP28 as a novel molecular therapeutic target of ovarian cancer. Biochem Biophys Res Commun. 638:184–191. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Peng J, Wu L, Shen X, Zhen X, Zhang Y, Ma H, Xu Y, Xiong Q, Zhu Q and Zhang P: The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells. J Biol Chem. 299:1048562023. View Article : Google Scholar : PubMed/NCBI | |
|
Prieto-Garcia C, Tomašković I, Shah VJ, Dikic I and Diefenbacher M: USP28: oncogene or tumor suppressor? A unifying paradigm for squamous cell carcinoma. Cells. 10:26522021. View Article : Google Scholar : PubMed/NCBI | |
|
Park HB and Baek KH: E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers. Biochim Biophys Acta Rev Cancer. 1877:1887362022. View Article : Google Scholar : PubMed/NCBI | |
|
Arita H, Nagata M, Yoshida R, Matsuoka Y, Hirosue A, Kawahara K, Sakata J, Nakashima H, Kojima T, Toya R, et al: FBXW7 expression affects the response to chemoradiotherapy and overall survival among patients with oral squamous cell carcinoma: A single-center retrospective study. Tumour Biol. 39:10104283177317712017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Ling T, Shi R, Shu Q, Li Y and Tan Z: Expression of FBXW7 in esophageal squamous cell carcinoma and its clinical significance. Zhonghua Zhong Liu Za Zhi. 37:347–351. 2015.(In Chinese). PubMed/NCBI | |
|
Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes PW, Iyengar PV, Muñoz-Couselo E, Nuciforo P, Cortés J, Nötzel C, et al: Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. J Exp Med. 215:1913–1928. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y and Tian H: Current development status of MEK inhibitors. Molecules. 22:15512017. View Article : Google Scholar : PubMed/NCBI | |
|
Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, et al: PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 22:1382023. View Article : Google Scholar : PubMed/NCBI | |
|
Jin J, He J, Li X, Ni X and Jin X: The role of ubiquitination and deubiquitination in PI3K/AKT/mTOR pathway: A potential target for cancer therapy. Gene. 889:1478072023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen M, Choi S, Wen T, Chen C, Thapa N, Lee JH, Cryns VL and Anderson RA: A p53-phosphoinositide signalosome regulates nuclear AKT activation. Nat Cell Biol. 24:1099–1113. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Marquard FE and Jücker M: PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol. 172:1137292020. View Article : Google Scholar : PubMed/NCBI | |
|
De Felice F and Guerrero Urbano T: New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors. Oral Oncol. 67:119–123. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Borgato GB, Borges GA, Souza AP, Squarize CH and Castilho RM: Loss of PTEN sensitizes head and neck squamous cell carcinoma to 5-AZA-2′-deoxycytidine. Oral Surg Oral Med Oral Pathol Oral Radiol. 130:181–190. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Psyrri A, Seiwert TY and Jimeno A: Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book. 2013:246–255. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tewari D, Patni P and Bishayee A, Sah AN and Bishayee A: Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Semin Cancer Biol. 80:1–17. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Vander Broek R, Mohan S, Eytan DF, Chen Z and Van Waes C: The PI3K/Akt/mTOR axis in head and neck cancer: Functions, aberrations, cross-talk, and therapies. Oral Dis. 21:815–825. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Yang G, Zhang W, Qin B, Ye Z, Shi H, Zhao X, Chen Y, Song B, Mei Z, et al: USP13: Multiple functions and target inhibition. Front Cell Dev Biol. 10:8751242022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S, Wang M, Chen D, Sun Y, Hung MC, et al: Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol. 15:1486–1494. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Qu Z, Zhang R, Su M and Liu W: USP13 serves as a tumor suppressor via the PTEN/AKT pathway in oral squamous cell carcinoma. Cancer Manag Res. 11:9175–9183. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Huang J, Ye Z, Wang J, Chen Q, Huang D and Liu H: USP13 mediates PTEN to ameliorate osteoarthritis by restraining oxidative stress, apoptosis and inflammation via AKT-dependent manner. Biomed Pharmacother. 133:1110892021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang K, Liu J, Li YL, Li JP and Zhang R: Ubiquitination/de-ubiquitination: A promising therapeutic target for PTEN reactivation in cancer. Biochim Biophys Acta Rev Cancer. 1877:1887232022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Li Y, Xiao Y, Yang M, Chen J, Jian Y, Chen X, Shi D, Chen X, Ouyang Y, et al: Nicotine-mediated OTUD3 downregulation inhibits VEGF-C mRNA decay to promote lymphatic metastasis of human esophageal cancer. Nat Commun. 12:70062021. View Article : Google Scholar : PubMed/NCBI | |
|
Geng W, Song H, Zhao Q, Dong K, Pu Q, Gao H and Lv Y: miR-520h stimulates drug resistance to paclitaxel by targeting the OTUD3-PTEN axis in breast cancer. Biomed Res Int. 2020:95127932020. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan L, Lv Y, Li H, Gao H, Song S, Zhang Y, Xing G, Kong X, Wang L, Li Y, et al: Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis. Nat Cell Biol. 17:1169–1181. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao M, Yang F, Sang C, Yan C and Wang Z: BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability. J Endocrinol Invest. 44:2165–2174. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Antonenko S, Zavelevich M and Telegeev G: The role of USP1 deubiquitinase in the pathogenesis and therapy of cancer. Acta Biochim Pol. 70:219–231. 2023.PubMed/NCBI | |
|
Xu J, Li B, Song W, Cao L, Zhu C and Lin S: Tumor suppressor functions of miRNA-375 in nasopharyngeal carcinoma through inhibition of ubiquitin-specific protease 1 expression. Int J Biochem Cell Biol. 141:1060922021. View Article : Google Scholar : PubMed/NCBI | |
|
Vucic D, Dixit VM and Wertz IE: Ubiquitylation in apoptosis: A post-translational modification at the edge of life and death. Nat Rev Mol Cell. 12:439–452. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schaefer A, Nethe M and Hordijk PL: Ubiquitin links to cytoskeletal dynamics, cell adhesion and migration. Biochem J. 442:13–25. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ulrich HD and Walden H: Ubiquitin signalling in DNA replication and repair. Nat Rev Mol Cell Biol. 11:479–489. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ma A, Tang M, Zhang L, Wang B, Yang Z, Liu Y, Xu G, Wu L, Jing T, Xu X, et al: Correction to: USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis. Oncogene. 41:16732022. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D, Li Q, Zang Y, Li X, Li Z, Zhang P, Feng C, Yang P, Cui J, Sun Y, et al: USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis. Cell Death Dis. 14:2642023. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Z, Chen Y, Chen R, Zhou B, Wang Y, Hong L, Wang Y, Wang J, Xu X, Huang Z and Chen W: HPV Enhances HNSCC chemosensitization by inhibiting SERPINB3 expression to disrupt the fanconi anemia pathway. Adv Sci (Weinh). 10:e22024372022. View Article : Google Scholar : PubMed/NCBI | |
|
Goldbraikh D, Neufeld D, Eid-Mutlak Y, Lasry I, Gilda JE, Parnis A and Cohen S: USP1 deubiquitinates Akt to inhibit PI3K-Akt-FoxO signaling in muscle during prolonged starvation. EMBO Rep. 21:e487912020. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y and Massagué J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Heldin CH, Miyazono K and ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 390:465–471. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Derynck R and Budi EH: Specificity, versatility, and control of TGF-β family signaling. Sci Signal. 12:eaav51832019. View Article : Google Scholar : PubMed/NCBI | |
|
Meulmeester E and Ten Dijke P: The dynamic roles of TGF-β in cancer. J Pathol. 223:205–218. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Britton WR, Cioffi I, Stonebraker C, Spence M, Okolo O, Martin C, Henick B, Nakagawa H and Parikh AS: Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 16:30472024. View Article : Google Scholar : PubMed/NCBI | |
|
Ibi H, Takahashi K, Harada H, Watabe T and Podyma-Inoue KA: Transforming growth factor-β signals promote progression of squamous cell carcinoma by inducing epithelial-mesenchymal transition and angiogenesis. Biochem Biophys Res Commun. 714:1499652024. View Article : Google Scholar : PubMed/NCBI | |
|
Itoh S and ten Dijke P: Negative regulation of TGF-beta receptor/Smad signal transduction. Curr Opin Cell Biol. 19:176–184. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Shinriki S, Jono H, Maeshiro M, Nakamura T, Guo J, Li JD, Ueda M, Yoshida R, Shinohara M, Nakayama H, et al: Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma. J Pathol. 244:367–379. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Thornton AM, Kinney MC, Ma CA, Spinner JJ, Fuss IJ, Shevach EM and Jain A: The deubiquitinase CYLD targets Smad7 protein to regulate transforming growth factor β (TGF-β) signaling and the development of regulatory T cells. J Biol Chem. 286:40520–40530. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Xing C, Deng Y, Ye C and Peng H: HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 11:234–251. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Z, Li H, Zhu J, Wang H and Jin X: The roles of E3 ligases in Hepatocellular carcinoma. Am J Cancer Res. 12:1179–1214. 2022.PubMed/NCBI | |
|
Semenza GL: Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 9:47–71. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wenger RH, Stiehl DP and Camenisch G: Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005:re122005. View Article : Google Scholar : PubMed/NCBI | |
|
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Gong L, Zhang W, Zhou J, Lu J, Xiong H, Shi X and Chen J: Prognostic value of HIFs expression in head and neck cancer: A systematic review. PLoS One. 8:e750942013. View Article : Google Scholar : PubMed/NCBI | |
|
Grethe C, Schmidt M, Kipka GM, O'Dea R, Gallant K, Janning P and Gersch M: Structural basis for specific inhibition of the deubiquitinase UCHL1. Nat Commun. 13:59502022. View Article : Google Scholar : PubMed/NCBI | |
|
Bishop P, Rocca D and Henley JM: Ubiquitin C-terminal hydrolase L1 (UCH-L1): Structure, distribution and roles in brain function and dysfunction. Biochem J. 473:2453–2462. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KC, Chen HH, Cheng KC, Liu TT, Lee KF, Teng CC, Huang CY, Hsieh MC and Kuo HC: Use of iTRAQ-based quantitative proteomic identification of CHGA and UCHL1 correlated with lymph node metastasis in colorectal carcinoma. J Cell Mol Med. 27:2004–2020. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Liang Y, Zhou S, Chen J and Wu C: UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5. Breast Cancer Res. 26:442024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang D, Fu Y, Tian G, Li J, Shang D and Zhou S: UCHL1 promotes proliferation and metastasis in head and neck squamous cell carcinoma and could be a potential therapeutic target. Oral Surg Oral Med Oral Pathol Oral Radiol. 133:684–697. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Hattori A, Takahashi S, Goto Y, Harada H and Kakeya H: Ubiquitin carboxyl-terminal hydrolase L1 promotes hypoxia-inducible factor 1-dependent tumor cell malignancy in spheroid models. Cancer Sci. 111:239–252. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, Bevilacqua A and Tesei A: 3D tumor spheroid models for in vitro therapeutic screening: A systematic approach to enhance the biological relevance of data obtained. Sci Rep. 6:191032016. View Article : Google Scholar : PubMed/NCBI | |
|
Günter J, Ruiz-Serrano A, Pickel C, Wenger RH and Scholz CC: The functional interplay between the HIF pathway and the ubiquitin system-more than a one-way road. Exp Cell Res. 356:152–159. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tejeda-Muñoz N and Robles-Flores M: Glycogen synthase kinase 3 in Wnt signaling pathway and cancer. IUBMB Life. 67:914–922. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gordon MD and Nusse R: Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 281:22429–22433. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Xie J, Huang L, Lu YG and Zheng DL: Roles of the Wnt signaling pathway in head and neck squamous cell carcinoma. Front Mol Biosci. 7:5909122020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang F, Zeng Q, Yu G, Li S and Wang CY: Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal. 18:679–687. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Moon JH, Lee SH and Lim YC: Wnt/β-catenin/Slug pathway contributes to tumor invasion and lymph node metastasis in head and neck squamous cell carcinoma. Clin Exp Metastasis. 38:163–174. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng N, Chu M, Lin M, He Y and Wang Z: USP7 stabilizes EZH2 and enhances cancer malignant progression. Am J Cancer Res. 10:299–313. 2020.PubMed/NCBI | |
|
Yamagishi M and Uchimaru K: Targeting EZH2 in cancer therapy. Curr Opin Oncol. 29:375–381. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Jin Q, Lee JE, Su IH and Ge K: Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci USA. 107:7317–7322. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang MJ, Chen DS, Li H, Liu WW, Han GY and Han YF: Clinical significance of USP7 and EZH2 in predicting prognosis of laryngeal squamous cell carcinoma and their possible functional mechanism. Int J Clin Exp Pathol. 12:2184–2194. 2019.PubMed/NCBI | |
|
Liu S, Qin Z, Mao Y, Zhang W, Wang Y, Jia L and Peng X: Therapeutic targeting of MYC in head and neck squamous cell carcinoma. Oncoimmunology. 11:21305832022. View Article : Google Scholar : PubMed/NCBI | |
|
Llombart V and Mansour MR: Therapeutic targeting of ‘undruggable’ MYC. EBioMedicine. 75:1037562022. View Article : Google Scholar : PubMed/NCBI | |
|
Dejure FR and Eilers M: MYC and tumor metabolism: Chicken and egg. EMBO J. 36:3409–3420. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Chen C, Song Z, Wang H, Ye M, Wang D, Kang W, Liu H and Qing G: EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation. Nat Commun. 13:122022. View Article : Google Scholar : PubMed/NCBI | |
|
Dou Y, Lin J, Shu H and Jiang N: Role of ubiquitin-specific peptidase 22 in carcinogenesis of human pharyngeal squamous cell carcinoma. Mol Med Rep. 10:2973–2978. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kim D, Hong A, Park HI, Shin WH, Yoo L, Jeon SJ and Chung KC: Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells. J Cell Physiol. 232:3664–3676. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Wen S, Wang B, Gao W, Zhang W, Meng X, Yang L and Kong L: Expression of cancer stem cell marker USP22 in laryngeal squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 49:479–482. 2014.(In Chinese). PubMed/NCBI | |
|
Shin E and Kim J: The potential role of YAP in head and neck squamous cell carcinoma. Exp Mol Med. 52:1264–1274. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Faraji F, Ramirez SI, Anguiano Quiroz PY, Mendez-Molina AN and Gutkind JS: Genomic hippo pathway alterations and persistent YAP/TAZ activation: New hallmarks in head and neck cancer. Cells. 11:13702022. View Article : Google Scholar : PubMed/NCBI | |
|
Segrelles C, Paramio JM and Lorz C: The transcriptional co-activator YAP: A new player in head and neck cancer. Oral Oncol. 86:25–32. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chan EH, Nousiainen M, Chalamalasetty RB, Schäfer A, Nigg EA and Silljé HH: The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 24:2076–2086. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC and Yaffe MB: TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19:6778–6791. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Pocaterra A, Romani P and Dupont S: YAP/TAZ functions and their regulation at a glance. J Cell Sci. 133:jcs2304252020. View Article : Google Scholar : PubMed/NCBI | |
|
Fang Y, Fu D and Shen XZ: The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta. 1806:1–6. 2010.PubMed/NCBI | |
|
Mtango NR, Sutovsky M, Susor A, Zhong Z, Latham KE and Sutovsky P: Essential role of maternal UCHL1 and UCHL3 in fertilization and preimplantation embryo development. J Cell Physiol. 227:1592–1603. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki M, Setsuie R and Wada K: Ubiquitin carboxyl-terminal hydrolase l3 promotes insulin signaling and adipogenesis. Endocrinology. 150:5230–5239. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mtango NR, Sutovsky M, Vandevoort CA, Latham KE and Sutovsky P: Essential role of ubiquitin C-terminal hydrolases UCHL1 and UCHL3 in mammalian oocyte maturation. J Cell Physiol. 227:2022–2029. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nishi R, Wijnhoven PWG, Kimura Y, Matsui M, Konietzny R, Wu Q, Nakamura K, Blundell TL and Kessler BM: The deubiquitylating enzyme UCHL3 regulates Ku80 retention at sites of DNA damage. Sci Rep. 8:178912018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Smits AH, van Tilburg GB, Jansen PW, Makowski MM, Ovaa H and Vermeulen M: An interaction landscape of ubiquitin signaling. Mol Cell. 65:941–955.e8. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tang J, Yang Q, Mao C, Xiao D, Liu S, Xiao L, Zhou L, Wu G and Tao Y: The deubiquitinating enzyme UCHL3 promotes anaplastic thyroid cancer progression and metastasis through Hippo signaling pathway. Cell Death Differ. 30:1247–1259. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Xiang Y, Xie Z, Fan M, Fang S, Wan H, Zhao R, Zeng F and Hua Q: USP14 positively modulates head and neck squamous carcinoma tumorigenesis and potentiates heat shock pathway through HSF1 Stabilization. Cancers (Basel). 15:43852023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang F, Ning S, Yu B and Wang Y: USP14: Structure, function, and target inhibition. Front Pharmacol. 12:8013282022. View Article : Google Scholar : PubMed/NCBI | |
|
Shi D, Wu X, Jian Y, Wang J, Huang C, Mo S, Li Y, Li F, Zhang C, Zhang D, et al: USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun. 13:56442022. View Article : Google Scholar : PubMed/NCBI | |
|
Ji J, Lv J, Lv M, Jing A, Xu M, Yuan Q, Ma X, Qian Q, Wang W, Geng T, et al: USP14 regulates heme metabolism and ovarian cancer invasion through BACH1 deubiquitination and stabilization. Biochem Biophys Res Commun. 667:186–193. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Tao L, Liu X, Jiang X, Zhang K, Wang Y, Li X, Jiang S and Han T: USP10 as a potential therapeutic target in human cancers. Genes (Basel). 13:8312022. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Pan J, Lin Y, Wu Y, Chen Y and Li H: Ceramide synthase 1 inhibits brain metastasis of non-small cell lung cancer by interacting with USP14 and downregulating the PI3K/AKT/mTOR signaling pathway. Cancers (Basel). 15:19942023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao C, Gong J, Bai Y, Yin T, Zhou M, Pan S, Liu Y, Gao Y, Zhang Z, Shi Y, et al: A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Cell Death Differ. 30:1–15. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, Dias-Santagata D, Koeva M, Stemmer SM, Whitesell L and Lindquist S: The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell. 158:564–578. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Carpenter RL and Gökmen-Polar Y: HSF1 as a cancer biomarker and therapeutic target. Curr Cancer Drug Targets. 19:515–524. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 13:9644422022. View Article : Google Scholar : PubMed/NCBI | |
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu K: Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI | |
|
Fasano M, Corte CMD, Liello RD, Viscardi G, Sparano F, Iacovino ML, Paragliola F, Piccolo A, Napolitano S, Martini G, et al: Immunotherapy for head and neck cancer: Present and future. Crit Rev Oncol Hematol. 174:1036792022. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang S, Li X, Huang L, Xu Z and Lin J: Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer. Front Immunol. 13:9884162022. View Article : Google Scholar : PubMed/NCBI | |
|
Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M and Donato NJ: Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 70:9265–9276. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Huang G, Liao J, Wang M, Huang Y, Tang M and Hao Y: USP9X increased tumor angiogenesis in mantle cell lymphoma by upregulation of CCND1-mediated SOX11. Mediterr J Hematol Infect Dis. 14:e20220482022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang FK, Ni QZ, Wang K, Cao HJ, Guan DX, Zhang EB, Ma N, Wang YK, Zheng QW, Xu S, et al: Targeting USP9X-AMPK axis in ARID1A-deficient hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 14:101–127. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Song N, Liu L, Liu X, Ding X, Song X, Yang S, Shan L, Zhou X, Su D, et al: USP9X regulates centrosome duplication and promotes breast carcinogenesis. Nat Commun. 8:148662017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Liu Y, Yang B, Cao H, Yang CX, Ouyang W, Zhang SM, Yang GF, Zhou FX, Zhou YF and Xie CH: Elevated expression of USP9X correlates with poor prognosis in human non-small cell lung cancer. J Thorac Dis. 7:672–679. 2015.PubMed/NCBI | |
|
Nanayakkara DM, Nguyen MN and Wood SA: Deubiquitylating enzyme, USP9X, regulates proliferation of cells of head and neck cancer lines. Cell Prolif. 49:494–502. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Potu H, Peterson LF, Kandarpa M, Pal A, Sun H, Durham A, Harms PW, Hollenhorst PC, Eskiocak U, Talpaz M and Donato NJ: Usp9× regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma. Nat Commun. 8:144492017. View Article : Google Scholar : PubMed/NCBI | |
|
Wu J, Guo W, Wen D, Hou G, Zhou A and Wu W: Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma. Cancer Med. 7:4004–4011. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pandruvada S, Kessler R and Thai A: Head and neck cancer treatment in the era of molecular medicine. Adv Cancer Res. 160:205–252. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Runnels J, Bloom JR, Hsieh K, Dickstein DR, Shi Y, Jones BM, Lehrer EJ and Bakst RL: Combining radiotherapy and immunotherapy in head and neck cancer. Biomedicines. 11:20972023. View Article : Google Scholar : PubMed/NCBI | |
|
Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, et al: Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. Clin Cancer Res. 28:2329–2338. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kitamura N, Sento S, Yoshizawa Y, Sasabe E, Kudo Y and Yamamoto T: Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma. Int J Mol Sci. 22:2402020. View Article : Google Scholar : PubMed/NCBI | |
|
Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, et al: Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 41:790–802. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Cai Y, Dodhia S and Su GH: Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. Oncotarget. 8:22203–22217. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bozec A, Ebran N, Radosevic-Robin N, Chamorey E, Yahia HB, Marcie S, Gautier M, Penault-Llorca F and Milano G: Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer. Head Neck. 39:151–159. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liao YM, Kim C and Yen Y: Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol. 3:222011. View Article : Google Scholar : PubMed/NCBI | |
|
Marret G, Isambert N, Rezai K, Gal J, Saada-Bouzid E, Rolland F, Chausson M, Borcoman E, Alt M, Klijanienko J, et al: Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Invest New Drugs. 39:1641–1648. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Nathan CO, Hayes DN, Karrison T, Harismendy O, Flores JM, Moore-Medlin T, Vokes EE, Gutkind JS, Neupane P, Mills G, et al: A Randomized multi-institutional phase II trial of everolimus as adjuvant therapy in patients with locally advanced squamous cell cancer of the head and neck. Clin Cancer Res. 28:5040–5048. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Poondla N, Chandrasekaran AP, Kim KS and Ramakrishna S: Deubiquitinating enzymes as cancer biomarkers: New therapeutic opportunities? BMB Rep. 52:181–189. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HR, Choi WC, Lee S, Hwang J, Hwang E, Guchhait K, Haas J, Toth Z, Jeon YH, Oh TK, et al: Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein. Nat Struct Mol Biol. 18:1336–1344. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hu T, Zhang J, Sha B, Li M, Wang L, Zhang Y, Liu X, Dong Z, Liu Z, Li P and Chen P: Targeting the overexpressed USP7 inhibits esophageal squamous cell carcinoma cell growth by inducing NOXA-mediated apoptosis. Mol Carcinog. 58:42–54. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshizaki T, Kondo S, Endo K, Nakanishi Y, Aga M, Kobayashi E, Hirai N, Sugimoto H, Hatano M, Ueno T, et al: Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Cancer Sci. 109:272–278. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kondo S, Seo SY, Yoshizaki T, Wakisaka N, Furukawa M, Joab I, Jang KL and Pagano JS: EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res. 66:9870–9877. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi E, Hwang D, Bheda-Malge A, Whitehurst CB, Kabanov AV, Kondo S, Aga M, Yoshizaki T, Pagano JS, Sokolsky M and Shakelford J: Inhibition of UCH-L1 deubiquitinating activity with two forms of LDN-57444 has anti-invasive effects in metastatic carcinoma cells. Int J Mol Sci. 20:37332019. View Article : Google Scholar : PubMed/NCBI | |
|
Ding W, Wang JX, Wu JZ, Liu AC, Jiang LL, Zhang HC, Meng Y, Liu BY, Peng GJ, Lou EZ, et al: Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells. Acta Pharmacol Sin. 44:2537–2548. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Kropp KN, Maurer S, Rothfelder K, Schmied BJ, Clar KL, Schmidt M, Strunz B, Kopp HG, Steinle A, Grünebach F, et al: The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma. Cancer Immunol Immunother. 67:935–947. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Wang T, Yang Q, Cheng S, Liu F, Yang G, Wang F, Wang R, Yang D, Zhou M, et al: Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer. Cell Oncol (Dordr). 45:951–965. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D and Anderson KC: A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 123:706–716. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nalawansha DA and Crews CM: PROTACs: An emerging therapeutic modality in precision medicine. Cell Chem Biol. 27:998–1014. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Noblejas-López MDM, Tébar-García D, López-Rosa R, Alcaraz-Sanabria A, Cristóbal-Cueto P, Pinedo-Serrano A, Rivas-García L and Galán-Moya EM: TACkling cancer by targeting selective protein degradation. Pharmaceutics. 15:24422023. View Article : Google Scholar : PubMed/NCBI | |
|
Henning NJ, Boike L, Spradlin JN, Ward CC, Liu G, Zhang E, Belcher BP, Brittain SM, Hesse MJ, Dovala D, et al: Deubiquitinase-targeting chimeras for targeted protein stabilization. Nat Chem Biol. 18:412–421. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Xue H and Jin J: Applications of protein ubiquitylation and deubiquitylation in drug discovery. J Biol Chem. 300:1072642024. View Article : Google Scholar : PubMed/NCBI |
